Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Inclusion Criteria:

Presence of at least one target liver or other intra-abdominal lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging: Target lesion must measure >=1.0 cm in long axis diameter on CT or MRI
The subject is able and willing to comply with study procedures and provide signed and dated informed consent.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Adequate organ function, including creatinine < 1.5 x ULN or estimated creatinine clearance >=500 mL/min (by the Cockcroft Gault equation) and total bilirubin <3x upper limit of normal (ULN).

Part B only:

No prior local therapy to target lesion.

If patient agrees to optional biopsy:

Presence of at least one target lesion amenable to percutaneous tumor biopsy in the judgment of Interventional Radiology
No history of bleeding diathesis.
Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy.
Planned treatment with agent targeting PI3K/mTOR pathway (either standard of care or investigational agent)

Exclusion Criteria:

Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.
Metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging.
Poorly controlled hypertension, defined as systolic blood pressure at study entry greater than 160 mm Hg or diastolic blood pressure greater than 100 mm Hg. The addition of anti-hypertensives to control blood pressure is allowed.
Congestive heart failure or New York Heart Association (NYHA) status ≥ 2.
A history of clinically significant EKG abnormalities, including QT prolongation (QTcF > 500 ms), a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry. Patients with rate-controlled atrial fibrillation/flutter will be allowed on study.
Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.